YWBCP Peer Support Network
If you've been diagnosed in the past year, and would like to talk with a woman who was also diagnosed at a young age and has completed treatment, contact Kim at 314-747-7156 or email@example.com. This network offers the unique opportunity to talk with someone who understands. There's no reason too big or small to reach out for support - we're here to help!
The National Comprehensive Cancer Network Announces AYA Guidelines
NCCN announces the availability of NCCN Guidelines for Patients®: Caring for Adolescents and Young Adults, a patient-friendly translation of the NCCN Guidelines® focused on people diagnosed with cancer between the ages of 15 and 39. Visit www.nccn.org for more information.
The Love/Avon Army of Women - Sign up for open research studies!
The Love/Avon Army of Women is recruiting 1 million women nationwide to researchers learn about causes, cure, and prevention of breast cancer. Women of all ages and ethnicities are encouraged to visit www.armyofwomen.org to learn more and sign up.
Urge your senators to support "The Accelerating the End of Breast Cancer Act (HR 1830, S 865)"
The National Breast Cancer Coalition has launched its "Deadline 2020" initiative, a call to action to end breast cancer by January 1, 2020. As part of this initiative, NBCC and SLBCC, our local affiliate, are urging you to support "The Accelerating the End of Breast Cancer Act," which would focus existing research funding in the areas of primary breast cancer prevention and metastatic disease. Visit www.breastcancerdeadline2020.org to sign the petition in support of this act, and contact Senators Claire McCaskill 202-224-6154 and Roy Blunt 202-224-5721 to ask for their support.
Online Survey for Young Breast Cancer Survivors
Are you a young woman diagnosed with breast cancer under the age of 45? Researchers from the University of Colorado - Denver are conducting a study to learn more about the unique experiences of young breast cancer survivors. Eligibility criteria include: diagnosed with any stage breast cancer between the ages of 19-45 years; any time post-treatment (except hormone treatment or antibody therapy); first diagnosis of breast cancer; not currently pregnant. Complete the online survey at: http://goo.gl/q6WNu. Feel free to contact Kellie Martens (firstname.lastname@example.org) at the University of Colorado - Denver with comments or questions.
PARP Inhibitor Study for People with Advanced, BRCA-Associated Breast Cancer
Women and men aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation may qualify for the BROCADE Study. The purpose of this study is to determine the safety and effectiveness of the PARP inhibitor, Veliparib, in combination with chemotherapy in patients with advanced hereditary breast cancer. Participants will receive investigational medication or placebo, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available. Eligibility criteria are: confirmed breast cancer that has spread beyond the breast and lymph node; BRCA1 or BRCA2 mutation; no more than one prior cancer treatment for metastatic breast cancer; healthy enough to be up and out of bed at least half the time; not pregnant or plan to conceive a child (and agree to use adequate contraception). For more info, visit www.brocadestudy.com/?utm_source=FORCEPartnership&utm_medium=Sponsorship&utm_campaign=BrocadeStudy.